Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04545333 · ClinicalTrials.gov registry record
The clonoSEQ® Watch Registry
A clinical trial, sponsored by Adaptive Biotechnologies.
- Terminated
- Registry status
- 465
- Enrollment target
NCT04545333 is a clinical trial that was terminated before completion, run by Adaptive Biotechnologies. The registered enrollment target is 465 participants.
The verdict
NCT04545333 was terminated before completion, sponsored by Adaptive Biotechnologies.
- TERMINATED
- Registry status
- 465 participants
- Enrollment target
Study Summary
This is a prospective, multicenter, observational study of adult patients with a diagnosis of acute lymphoblastic leukemia (ALL), multiple myeloma (MM), chronic lymphocytic leukemia (CLL), or non-Hodgkin lymphoma (NHL). This study will enroll up to 528 patients in up to 50 sites in the United States and collect data with regard to use of the clonoSEQ MRD assay in the management of lymphoid malignancies.
Interventions
- DIAGNOSTIC_TEST clonoSEQ Assay
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 465 participants |
| Start Date | 2020-10-13 |
| Est. Completion | 2023-10-01 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04545333
The ClinicalTrials.gov registry entry for NCT04545333 describes a study currently listed as terminated, categorized as an unspecified phase. The registered enrollment target is 465 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Adaptive Biotechnologies, which has 7 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which clonoSEQ Assay is the first listed.
NCT04545333 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04545333 about?
NCT04545333 is a clinical study titled "The clonoSEQ® Watch Registry". This is a prospective, multicenter, observational study of adult patients with a diagnosis of acute lymphoblastic leukemia (ALL), multiple myeloma (MM), chronic lymphocytic leukemia (CLL), or non-Hodgkin lymphoma (NHL). This study will enroll up to 528 patients in up to 50 sites in the United States...
What is the current status of trial NCT04545333?
This trial is currently terminated. The enrollment target is 465 participants. The study started on 2020-10-13. Estimated completion is 2023-10-01.
What interventions are being tested in trial NCT04545333?
The interventions under investigation include: clonoSEQ Assay (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT04545333?
This trial is sponsored by Adaptive Biotechnologies, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.